Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood with an incidence of 10-19/100.000 children below the age of 16 years, and it is also a major cause of acquired disability and impairment of quality of life in childhood.[1-5] The term JIA, like its predecessors juvenile rheumatoid arthritis and juvenile chronic arthritis, is an umbrella term for clinical patterns of arthritis in children. By definition JIA encompasses a group of clinically heterogenous arthritides that begin prior to age 16 years, are of unknown cause,and present with joint pain, stiffness and swelling that persists for longer than six weeks.[1,7] According to the International League of Associations for Rheumatology (ILAR) classification, JIA is subdivided into seven categories which are different from each other and from adult rheumatoid arthritis (RA).[8,9] The ILAR classification is based on the number of joints affected, the presence or absence of specific serologic findings and systemic manifestations as outlined in table 1.
Without appropriate treatment, JIA may result in devastating consequences. Children may experience permanent disability from joint destruction, growth deformities or blindness. In the case of the systemiconset form of JIA (SOJIA), untreated disease may even result in multiple organ failure and death. Although the outcome for children who have JIA has improved in recent years, it is still less than ideal. Traditionally, the overall prognosis has been thought to be good with up to 60% of cases entering remission before adulthood,[5,10] but newer studies have not been performed to address this issue. Various studies have shown that 25% to 70% of children with JIA will still have ongoing, active disease 10 years after onset[10,11] and ≤35% of patients, regardless of the category of JIA, demonstrated a state of disease inactivity of 12 months or longer while off their medication regimen. These studies indicate that many patients diagnosed with JIA will be exposed to extended periods of medication throughout their lifetimes.
Conventional therapy consists of disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), as the most common first-line DMARD and non-steroidal anti-inflammatory drugs (NSAIDs), with the avoidance of systemic corticosteroids. More recently, intra-articular corticosteroid injections have been included in the treatment approach, especially in patients with oligoarthritis. Only MTX has proven to be effective and safe in large controlled trials. Nevertheless, in many cases, inefficacy, especially in patients with polyarticular and SOJIA or intolerance to MTX, has led investigators to try other treatment regimens. Prior to the era of biologicals, more than 25% of polyarticular and nearly 50% of systemic patients with JIA at five years after onset had functional limitations, and two-thirds had radiographically evident damage. Because none of the available drugs has curative potential, the primary therapeutic goals are to control symptoms, to normalize joint function and to avoid long-term joint damage. The approach to treatment depends on the assessment of individual needs and the disease subtype. Other comorbidities, such as the presence of uveitis, may influence treatment decisions. The present article will provide a brief update of clinical trial results and focus on recent evidence on the safety and efficacy of biologicals in the treatment of JIA.
Prior to the development of the pediatric core set and the American College of Rheumatology Pediatric 30 response criteria (ACR Pedi 30) in 1997, there had been no single, uniform definition of improvement for use in clinical trials of JIA(Table 2). The ACR Pedi 30 is used as the primary outcome measure for trials of biologic agents and second line therapies. Though not formally prospectively evaluated, the ACR Pedi 20, 50, 70, and 90 measures are also used as outcome measures in pediatric trials. The primary goal in the management of JIA is the achievement and maintenance of remission. Clinical criteria defining the disease state as inactive disease (ID) or clinical remission (CR) was developed in 2004 (Table 3). This definition includes six parameters, all of which have to be satisfied for a patient to be considered to have ID. However, they were modified recently and three changes were made to the provisional criteria (Table 3).
Biologic agents have been designed to target key cytokines implicated in JIA including tumor necrosis factor-α (TNF-α), Interleukin-1 (IL-1), and IL-6 as well as signaling molecules involved in the regulation of T-cell and B-cell lymphocyte responses. In general TNF-α inhibitors are more beneficial for children with polyarticular disease than in those with SOJIA. This difference may be due to different cytokines underlying the inflammatory response for each subtype of disease. Interleukin-1 and IL-6 rather than TNF-α may be the predominant proinflammatory cytokines in SOJIA.[21-23] Thus, biological agents that target IL-1 and IL-6 activity appear to be more successful in treating patients with SOJIA.
TNF-α INHIBITORS IN JUVENILE IDIOPATHIC ARTHRITIS
Tumor necrosis factor-α is a proinflammatory cytokine. Elevated TNF-α levels have been identified in plasma and synovial fluid in patients with JIA justifying that it is a major contributor to the inflammatory synovitis and joint damage in JIA. Tumor necrosis factor-α inhibitors are biological agents that block the immunological effects of this inflammatory mediator. Inhibitors of TNF-α were evaluated for efficacy in controlling JIA and have been shown to be highly effective in the treatment of JIA patients whose disease has been unresponsive to traditional therapies.[25,26] It has become common practice to move directly to anti-TNF therapy for the treatment of arthritis in children who have failed to respond adequately to MTX or who have been unable to tolerate MTX due to adverse effects.[27,28] There are three TNF-α inhibitors available for clinical use in the treatment of JIA: Etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira).
Etanercept (Enbrel) is a soluble p75 TNF receptor fusion protein coupled to the Fc (fragment crystallizable region) fragment of immunoglobulin G1 (IgG1) that acts competitively to inhibit the binding of both TNF-α and TNF-β to their cell surface receptors. Etanercept binds its target cytokine only when it is in serum and lowers the quantity of free TNF-α available for the maintenance of the inflammatory synovitis of JIA. Etanercept is administered as a subcutaneous injection 1-2 times per week. The TNF inhibitor etanercept is the first biological approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate to severe polyarticular JIA in children aged two years and older. It can be used alone or as an adjunct to MTX.
Tumor necrosis factor-α inhibitors, including etanercept, appear to have a more rapid onset of clinical effect than conventional DMARDs. In general, clinical improvement should be seen within 4-12 weeks.[27,29] However, these biologicals have not been shown to induce long-term clinical remission while patients were off medication. In a multicenter, randomized controlled trial (RCT), Lovell et al. enrolled 69 children aged 4 to 17 years with DMARDrefractory polyarticular JIA. In a three-month open label phase, all patients received etanercept at a dose of 0.4 mg/kg twice a week and nearly 75% of patients achieved an ACR Pedi 30. Dramatic improvements were achieved within weeks after commencement of therapy. Those patients who met the predefined definition of response at three months were randomized to continue etanercept or be switched to a placebo for four months. In the double-blind part of the study, 81% of the patients who were randomized to a placebo demonstrated disease flare compared with 28% of those who continued on etanercept. Thus, in most children, etanercept’s effects cease within a few weeks of its discontinuation. This study also showed that etanercept produced significant improvement in disease activity when used in the absence of DMARDs and appeared to be less effective in patients with SOJIA. Etanercept has demonstrated sustained improvement in the signs and symptoms of polyarticular-course JIA with an acceptable safety profile in an open-label extension (OLE) of a RCT at four and eight years.[31,32] At an eight-year follow-up, an ACR Pedi 70 was achieved by 61% of patients.
A 2008 systematic review of synthetic and biologic DMARD therapy for RA in adult patients concluded that anti-TNF monotherapy was similar in efficacy to treatment with MTX alone. The combination of an anti-TNF agent with MTX reduced disease activity more than did anti-TNF monotherapy or MTX alone. In children, nonrandomized open-label studies of the TNF inhibitors etanercept and infliximab have shown that these biologicals safely control active disease when used in combination with traditional therapies.[34,35] In 2008, a German registry also provided information on 431 children treated either with etanercept alone or with the combination of etanercept and MTX. At 12 months of follow up, the number of patients with JIA reaching a ACR Pedi 70 response was significantly higher in the etanercept and MTX group than in the etanercept monotherapy group.
Etanercept can induce disease remission and prevent both clinical and radiological disease progression with significant improvements in symptoms, function and quality of life.[37,38] In another small study, bone mineral status improved in patients who had responded to and continued etanercept treatment for more than one year.
Currently, little is known about when or how to stop etanercept in patients with JIA when a good clinical response is reached. Prince et al. suggest that patients with JIA should meet the criteria of clinical remission of medication for at least 1.5 years before considering discontinuation of etanercept and then taper off it carefully. In addition, issues such as whether etanercept should be used before MTX (faster onset of action, possibly more effective and less toxic) remain to be resolved. As more biologic agents become available over the next decade, there may be dramatic changes in our approach to the treatment of JIA.
Infliximab (Remicade) is a chimeric mouse-human monoclonal antibody (mAb) that binds specifically to human TNF-α with high affinity (mAbs have a higher affinity for a given cytokine than do soluble receptors like etanercept) and neutralises the biological activity of TNF-α by inhibiting its binding to its receptor. In JIA, MTX must be added to infliximab to prevent the development of neutralising antibodies to infliximab that could reduce its therapeutic efficacy. Monoclonal antibodies (infliximab and adalimumab) bind their target not only when it is free in the serum (like etanercept does), but also when it is bound to the cell surface. They do not bind TNF-β. They have a higher affinity for a given cytokine than do soluble receptors. Like etanercept, they lower the quantity of TNF-α available to maintain an inflammatory response. İnfliximab is given as an intravenous infusion on a monthly to eight-weekly timetable. İnfliximab has FDA approval for use in adult RA, psoriasis and adult and pediatric Crohn’s disease, but not in JIA.
In a multicenter RCT, Ruperto et al. enrolled 122 children aged 4 to 17 years with polyarticular JIA refractory to MTX and randomized patients to receive infliximab (3 mg/kg/dose) or a placebo for 14 weeks. After 14 weeks, all children received infliximab through week 44. Patients received MTX plus infliximab 3 mg/kg through week 44, or MTX plus placebo for 14 weeks followed by MTX plus infliximab 6 mg/kg through week 44. At 14 weeks, a higher proportion of patients randomized to infliximab 3 mg/kg had an ACR Pedi 30 response when compared with patients in the placebo group, but this difference was not statistically significant. By week 52, clinical responses meeting the ACR Pedi 50 and ACR Pedi 70 criteria were reached by 70% and 52% of the patients respectively. There were no statistically significant differences between the infliximab dose groups. Ruperto et al. also assessed the long-term safety and efficacy of MTX plus two infliximab dosages (3 mg/kg or 6 mg/kg) in a threeyear OLE. At week 204, the proportions of patients achieving ACR-Pedi 30/50/70/90 response criteria and inactive disease status were 44%, 40%, 33%, 24%, and 13% respectively, and they concluded that in the limited population of JIA patients remaining in the study through four years, infliximab was safe and effective even though it was associated with a high patient discontinuation rate.
One small observational study compared the administration of infliximab to etanercept in children with polyarticular JIA who had not responded to conventional DMARDs and showed similar results (ACR Pedi 50 improvement of 80 to 90 percent) in the two groups after 12 months of treatment.
One of the unique and distressing complications of JIA is a chronic, non-granulamatous uveitis. Tynjälä et al. enrolled 45 patients to compare the efficacy of infliximab with that of etanercept in the treatment of chronic uveitis; 24 patients were receiving etanercept and 21 were receiving infliximab. Patients who were taking infliximab were more likely to improve than those taking etanercept. Richards et al. and Rajaraman et al. each reported six cases of JIAassociated uveitis which were poorly responsive to other therapies. These patients were then treated with infliximab and had significant improvement under this therapy. Recently, the results of a multinational survey were reported. In this study etanercept was used in 34 patients and infliximab in 25 patients. The response to etanercept was favourable in about 50% of the cases, moderate in about 15%, and poor in about 35%, and for infliximab the response was favourable in about 69% of the cases, moderate in about 31%, and poor in 0%. These studies demonstrate that infliximab is more effective than etanercept in the treatment of refractory uveitis.
Adalimumab (Humira) is a recombinant fully human mAb which is administered either weekly or, more commonly, every other week as a single subcutaneous injection rather than by intravenous infusion. Adalimumab is associated with a lower risk of antibody formation compared with infliximab because of its fully humanised structure. In 2008, adalimumab was approved by the FDA as the second TNF-α inhibitor for the treatment of moderate to severe JIA in patients aged four years and older.
In a multicenter, randomized, medicationwithdrawal study, Lovell et al. enrolled 171 children aged 4 to 17 years with active polyarticular JIA. Children were stratified according to MTX use and received adalimumab subcutaneously every other week for 16 weeks. In a manner similar to the etanercept trial, after an open-label lead-in phase of 16 weeks, patients with ACR Pedi 30 response were randomly selected in a double blind manner to receive adalimumab or a placebo for an additional 32 weeks. In the second phase of the study, patients receiving adalimumab had significantly fewer flare-ups than patients in the placebo group regardless of whether they received MTX or not. Adalimumab demonstrated sustained improvement during two years of treatment. After 104 weeks of OLE treatment, the proportions of patients achieving ACR-Pedi 50/70/100 response criteria were 86%, 77%, and 40%, respectively.
Eighteen patients with uveitis were treated with adalimumab. The patients had all failed to respond to systemic steroids, cyclosporin, MTX, leflunomide, etanercept or infliximab. Sixteen out of 18 patients had good responses to adalimumab. In another retrospective observational study by Tynjälä et al., of 20 patients with chronic uveitis treated with adalimumab, 19 of them had been previously treated with infliximab or etanercept. Of the 20 patients, seven showed improved activity, one showed worsening activity, and twelve showed no change in the activity of uveitis. The mean number of flares/year decreased from 1.9 to 1.4 during adalimumab treatment, but this change was not significant. These studies suggest that adalimumab is a potential treatment option in JIAassociated uveitis, even in patients not responsive to other previous anti-TNF therapies.
There is no clear evidence to support the superiority of one TNF-α inhibitor over another and failure to respond to one agent does not preclude response to another.[50,51] In one small study, it was shown that using a third anti-TNF agent, adalimumab, can be efficacious in patients with JIA refractory to etanercept and/or infliximab.
Adverse effects of anti TNF-α biological agents
In order to use TNF-α inhibitors appropriately, it is important to be aware of potential treatment-related adverse effects (AEs) of these biologicals and the differences between them (Table 4). As well as with other DMARDs, SOJIA is at a greater risk for AEs than non-systemic JIA categories.
The most common AEs of TNF-α inhibitors are injection site reactions to subcutaneously administered drugs (etanercept and adalimumab) or infusion reactions (IRs) with infliximab. The cutaneous injection site reaction consists of local erythema and swelling which usually subsides within 24 hours. Transient injection site reactions are described in about 39% of patients with JIA on etanercept. In addition to the adverse effects reported above, there is greater immediate pain at the site of adalimumab injections when compared to etanercept, but this is generally an inconvenience that children find bearable. Infusionrelated reactions were defined as any adverse event that occurred during or within one hour following completion of an infusion. Infusion reactions are the most common AEs in patients treated with infliximab (26-38%)[41,52] and the reason for withdrawal among those receiving infliximab. These reactions are possibly due to immune responses against the mostly humanized mouse monoclonal antibody. In the international trial, IRs occurred in approximately 26% and 32% of patients from weeks 0-52 and 52-204 (OLE) respectively, with a higher incidence in patients positive for antibodies to infliximab, and were more frequent in patients treated with the lower 3 mg/kg dosage than the 6 mg/kg dose.[41,42] Serious IRs occurred in eight patients wherein five patients had a possible anaphylactic reaction. Gerloni et al. enrolled 163 children (68 infliximab, 95 etanercept). In their trial, the greater number of patients who presented AEs with infliximab (62.9%) versus those with etanercept (54.3%) was due to IRs (sensation of thoracic constriction, dyspnea, flushing, urticaria). Infusion reactions were the most common AEs (38.3%), and 20.1% of patients suspended treatment because of severe IR relapse. In this study, 12 patients receiving etanercept manifested a diffuse cutaneous reaction that led to withdrawal in only two patients. Most centers report a similarly increased incidence of side effects in children treated with mAbs, especially infliximab relative to etanercept. Since adalimumab is also administered subcutaneously, but only every other week, this mAb is at least administered as easily as etanercept.
One of the major concerns with infliximab is the development of human anti-chimeric antibodies (HACA) that neutralise the drug, thereby limiting its long-term efficacy or causing IRs. In an international trial, 25% of all patients had antibodies to infliximab with a higher incidence in the infliximab 3 mg/kg group (38%) compared with the infliximab 6 mg/kg group (12%). Infliximab seems to be more frequently responsible for newly induced anti-nuclear antibody (ANA) and anti-double stranded DNA (anti-dsDNA) antibody. During the OLE, newly positive ANA and anti-dsDNA occurred in 26% and 7% of patients from weeks 52-204. However, only rare cases of druginduced systemic lupus erythematosus (SLE), discoid lupus erythematosus (LE) and cutaneous vasculitis are described. In another international trial, Lovell et al. reported that approximately 16% of the patients had anti-adalimumab antibodies. This percentage is greater than the 5% observed during clinical trials of adult patients with RA. Positive anti-adalimumab antibody tests were less frequent among those receiving concomitant MTX than among those receiving adalimumab monotherapy.
Serious adverse events (SAEs) are defined as events that are fatal or life-threatening, require hospitalization or prolong an existing hospitalization. SAEs cause a persistent or significant disability or incapacity, a congenital anomaly, or birth defect. Etanercept offers an acceptable safety profile in long-term treatments. The long-term safety profile of etanercept was maintained for up to eight years of continuous drug use. Exposure-adjusted rates of SAEs did not increase over time, and the most common new SAEs reported beyond four years of drug exposure were flare or worsening of disease. Between the fourth and eighth year of follow-up, a single case of pyelonephritis was the only additional infection reported. It is thought that the three TNF-α inhibitors will share a similar long-term side effect.
The most important adverse effect of anti-TNF-α therapy is the increased risk of severe infections (e.g. sepsis, pneumonia, herpes simplex and zoster infection, pyelonephritis). After four years of an international trial of etanercept, the overall rate of SAEs was 0.13 and of serious infections was 0.04 per patient-year. The overall rate of SAEs (0.12 per patient-year) did not increase with long-term exposure to etanercept. Similarly, SAEs occured only in 14/171 patients, seven of whom had serious infections in the adalimumab trial. In the infliximab trial, however, the overall rate of SAEs (24/117) was higher, six of whom had serious infections. In addition, there may be an increased risk of opportunistic infections, particularly fungal (e.g. histoplasmosis or coccidioidomycosis) with the use of these agents. In patients who develop serious infections, the TNF-α blocker should be ceased, at least until the complete resolution of the infection. The reactivation of silent tuberculosis (TB), definitely related to TNF-α inhibition, has completely disappeared as TB screening and prophylaxis are now the rule before anti- TNF-α therapy. Infliximab is associated with the greater risk.
Over an 11-year period (1998-2009), 48 cases of malignancies in children with a TNF inhibitor have been reported to the FDA Adverse Event Reporting System. Half of them were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma; the rest included leukemia, melanoma, and solid organ cancers. Therefore, the FDA concluded that there is an increased risk of malignancy with TNF blockers. However, due to the relatively rare occurrence of these cancers, the limited number of pediatric patients treated with TNF blockers, and the possible role of other immunosuppressive therapies used concomitantly with TNF blockers, the FDA is unable at this time to fully characterize the strength of the association between using TNF blockers and developing a malignancy. New-onset or relapsing central nervous system (CNS) demyelinating disorders and neuropsychiatric AEs (depression, headache, vertigo, fatigue, hyperactivity, nervousness, anxiety, pain amplification, panic attacks, anorexia nervosa, optic neuropathy, hypoglossal paralysis) have been reported, especially in patients using etanercept. New-onset inflammatory bowel diseases (IBD) have also been detected in patients treated with etanercept. Another concern with TNF-α blockers, especially with etanercept, is the possible reactivation of chronic iridocyclitis (CIC). TNF-α inhibitors are effective in treating JIA and have acceptable safety profiles, but because of all these possible AEs, it is suggested that these biologic agents be used in patients with severe disease that is refractory to conventional therapy.
Interleukin-1 is a proinflammatory cytokine that triggers the production of proinflammatory prostoglandins as well as such other proinflammatory cytokines as IL-6 and TNF-α. Pascual et al., reported that IL-1 is a major mediator of the inflammatory cascade that underlies SOJIA. This study demonstrated that sera from patients with SOJIA could provoke IL-1 synthesis in tissue cultures of mononuclear cells from healthy controls, and this cytokine represents a target for therapy in this disease. Anakinra is currently in use in children with JIA while several other IL-1 inhibitors (rilonacept and canakinumab) are under investigation.
Anakinra (Kineret) is a recombinant IL-1 receptor antagonist (IL-1 Ra) that is approved for use in RA. Because of its short half-life, it is administered daily by subcutaneous injection (1-2 mg/kg/day). The Anakinra in Systemic-Onset Juvenile Idiopathic Arthritis trial (ANAJIS trial) was the the only double-blind RCT which tested anakinra efficacy in 24 patients with refractory SOJIA. Preliminary results reported in abstract form demonstrated that at one month, there was a significant difference in the response rate between patients treated with anakinra (8/12) and a placebo (1/12). Ten patients from the placebo group switched to anakinra at month one and nine were responders at month two. Gene expression profile analyses showed a set of gene pathways dysregulated in SOJIA whose expression dramatically changed upon anakinra treatment.
The first report on the effectiveness of IL-1Ra in SOJIA was presented in 2002. In an open-label study by Reiff, 80 patients with various forms of JIA were treated with anakinra; patients with SOJIA had a better response to anakinra than did those with other types of JIA (11/15 responded to anakinra). A similar recent RCT of anakinra (1mg/kg/day; maximum 100 mg/day) versus placebo in 50 patients with JIA by Ilowite et al. was unable to demonstrate significant efficacy of the drug. Subgroup analysis, however, showed that response rates may be higher among patients with SOJIA. Recent case reports demonstrated that treatment with IL-1 Ra (anakinra) led to rapid and sustained remission within a few days following the initiation of anakinra injections in patients with SOJIA who had been resistant to conventional DMARDs including TNF-blockade.[21,58-60] An initial case series reported by Pascual et al. reported a dramatic response to IL-1 blockade among SOJIA patients with six out of nine patients treated with anakinra achieving complete remission and two having improvement in symptoms. The results obtained in this case series support the use of anakinra as second-line therapy in children with SOJIA who have failed to respond to standard therapy.
Lequerré et al. recently described 20 SOJIA patients treated with anakinra and found marked and sustained improvement in less than half of the cases. Similarly, Gattorno et al. described a variable response of patient’s arthritis to anakinra in their series of 22 cases. In addition, Zeft et al. reported that arthritis was less improved compared with the general systemic symptoms of the disease. These observations indicate that although anakinra is considered to be effective in SOJIA, there is a group of patients who are anakinraresistant. The blockade of IL-1 signalling has a dramatic and sustained effect in some patients with the cessation of symptoms and a significant decrease of acute phase markers. The large group of partial responders and non-responders are suggestive of pathological processes that are independent of the IL-1 pathway.[64,65]
Injection site reactions (itch and/or erythema) and injection pain with daily subcutaneous medication are frequent local effects of anakinra[60,61,63] which may be so severe as to require the stoppage of medication. In the study by Zeft et al., over half of the patients reported localized pain or swelling at their injection sites. Similar to TNF-α inhibitors, IL-1 blockade increases the risk of infections. Anakinra is not recommended in a combined regimen with a TNF inhibitor because of an increased frequency of serious adverse events, including serious infections. In the ANAJIS trial, eight patients discontinued anakinra before month 12. Two patients (both on placebos) had painful injections during the double-blind phase, one had ileocolic symptoms leading to the diagnosis of Crohn’s disease, and one had a case of transient hepatic cytolysis. There was also a lack of efficacy or a disease flare in four cases. Varicella, localized herpes, leishmaniasis and EBV infections have been described in children with SOJIA receiving anakinra.[61,63] Three cases of macrophage activation syndrome (MAS) have also been described.[62,63] Anakinra has also been used to sufficiently treat MAS in SOJIA patients.[67,68] Without well-designed trials, the attributability of these findings remains unclear, and the ultimate long-term safety profile of anakinra needs to be determined.
Rilonacept (IL-1 Trap/Arcalyst) is a long-acting IL-1 blocker currently undergoing trials in children with SOJIA. Rilonacept is a recombinant fusion protein that combines IL-1 receptor protein components with the Fc portion of the human immunoglobulin molecule. Unlike anakinra, which requires daily dosing, rilonacept is administered once a week. Preliminary results of a double-blind, placebo-controlled study of rilonacept (2.2 to 4.4 mg/kg/week) in SOJIA were reported by Lovell et al. in abstract form. Of the 21 patients enrolled in the trial, 12 remain in the openlabel study and have had good responses to rilonacept with 10 patients achieving an ACR Pedi 70 response at 42 weeks. Six out of seven patients who had failed to respond to anakinra were found to improve on rilonacept. Adverse events were mild or moderate in severity included generalized rash and mood alteration. SAEs included exacerbation of pancytopenia and MAS. The OLE study on rilonacept in SOJIA was presented at the ACR 2009 meeting. In this long-term OLE study, sustained responses were observed in clinical and laboratory assessments in over 50% of patients with SOJIA at two years. There was a significant reduction in daily prednisone dosage. No deaths, malignancies, or serious infections occurred. The authors suggested that chronic IL-1 blockade with rilonacept was generally safe and well-tolerated.
Canakinumab (ACZ885) is a fully humanized mAb which binds specifically to the β isoform of IL-1 (IL-1β) and neutralizes the bioactivity of human IL-1β. It is administered as either a subcutaneous injection or an intravenous infusion. Canakinumab shows encouraging efficacy and is well tolerated in children with SOJIA according to a new phase II study presented at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark. This open-label staggered dose-escalation study assessed 23 children with active disease receiving a single subcutaneous injection of canakinumab in the dose range 0.5-9 mg/kg. Of those patients who responded to treatment (59% of initial enrollers), 100% achieved the ACR Pedi 50 score within only 15 days of receiving canakinumab. Adverse events were predominantly mild to moderate in severity and included infections and gastrointestinal disorders. SAEs including worsening nausea in a patient with a medical history of gastritis and EBV infection in another patient relating to canakinumab resolved during treatment. Early clinical trials have established the administration of canakinumab every two weeks to be safe and effective offering a considerable advantage over existing treatment with anakinra which must be injected daily and which is often poorly tolerated by patients.
IL-6 INHIBITOR: TOCILIZUMAB
Tocilizumab (Roactemra/Actemra/MRA) is a recombinant humanized monoclonal antibody that acts as an IL-6 receptor antagonist that has not yet been approved by the FDA for the treatment of RA or JIA. Interleukin-6 has both proinflammatory and anti-inflammatory effects. Plasma levels of IL-6 have been demonstrated to correlate with disease activity in JIA patients, and particularly elevated IL-6 levels have been noted in patients with SOJIA. In general, patients with SOJIA have a higher rate of treatment failure with TNF-α inhibitors than those with other chronic arthritis subtypes indicating that TNF-α is not the only cytokine implicated in the pathogenesis of the disease. Although it is likely that the blockade of IL-1 has a dramatic and sustained effect in some patients with SOJIA, the large group of partial responders and non-responders suggests pathological processes independent of the IL-1 pathway. Therapy with an anti-IL-6-receptor antibody (tocilizumab) revealed much better response rates in two phase II studies in SOJIA[73,74] and, more recently, in poly- and oligoarticular onset disease. A randomized clinical trial is needed to define efficacy and to identify the proper target population. This response rate is likely to be due to the fact that IL-6 can be stimulated by IL-1 and TNF; therefore, a blockade of IL-6 will take care of processes that come mainly from the IL-1 or TNF pathways as well other sources of stimulation of IL-6 in this disease.
In a phase III trial by Yokota et al., 56 children (aged 2-29 years) with SOJIA refractory to conventional treatment were given three doses of tocilizumab 8 mg/kg every two weeks as intravenous infusions during a six week open-label lead-in phase. The trial design was similar to the etanercept trial. Patients who achieved ACR Pedi 30 response and C-reactive protein concentration (CRP) of less than 5 mg/L were randomly assigned to receive a placebo or continue tocilizumab treatment for 12 weeks. Patients responding to tocilizumab and needing further treatment were enrolled in an OLE phase for at least 48 weeks. After the end of the openlabel phase, ACR Pedi 30, 50, and 70 responses were achieved by 51 (91%), 48 (86%) and 38 (68%) of patients respectively. Forty-three patients continued to the double-blind phase. Four (17%) of the 23 patients in the placebo group compared to 16 (80%) of the 20 patients in the tocilizumab group maintained an ACR Pedi 30 response and a CRP concentration of less than 15 mg/L. ACR Pedi 30, 50, 70 responses were achieved by 47 (98%), 45 (94%) and 43 (90%) of 48 patients, respectively. SAEs occured in 13 of 50 patients during the OLE phase. These included anaphylactoid reactions, gastrointestinal hemorrhages and bronchitis.
Interleukin-6 may also play a role in complications of SOJIA such as growth impairment, systemic osteoporosis and amyloidosis. In this respect, in a small group of SOJIA patients, cartilage oligomeric matrix protein (COMP) levels were found to be lower than controls and they markedly increased under tocilizumab therapy. These findings suggested that in SOJIA patients, the growth cartilage turnover was suppressed during the active disease phase, but it improved in the remission phase after tocilizumab treatment.
T-CELL COSTIMULATION MODULATOR; ABATACEPT
Abatacept (Orencia/CTLA4-Ig) is a fully human, soluble fusion protein with a unique mechanism of action. Abatacept consists of the extracellular domain of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the Fc portion of the immunoglobulin G1 (IgG1). CTLA4-Ig binds with either CD80 (B7-1) or CD86 (B7-2) on antigen-presenting cells, thereby acting as a competitive inhibitor of the CD28-B7 costimulatory interaction and preventing the second activation signal received by T cells via CD28. Abatacept thus downregulates T-cell stimulation and potentially affects many downstream cytokines and cell types that have been implicated in the pathogenesis of JIA.
In 2008, abatacept was approved by the FDA for treatment of patients aged six years or older with moderate to severe polyarticular JIA. The European Medicines Agency (EMEA) also recently (2010) approved abatacept in combination with MTX for the treatment of moderate to severe polyarticular JIA in pediatric patients six years of age and older as a second line biologic after TNF inhibitors. Abatacept has been studied in a double-blind, randomized controlled withdrawal trial including 190 children aged 6-17 years old with active polyarticular JIA refractory to at least one previous DMARD agent including anti-TNF agents. The design of this pivotal study was similar to trials of the anti-TNF agents (etanercept and adalimumab) and tocilizumab. All patients were given 10 mg/kg of abatacept intravenously in the open-label period of four months. At the end of the open-label treatment period, two-thirds of the 190 enrolled patients had improved by 30% or more according to ACR Pedi response criteria. Of the patients who did respond to abatacept, 60 were randomly assigned to receive 10 mg/kg abatacept at 28-day intervals for six months, and 62 were randomly assigned to receive a placebo. Flares of arthritis occured in 33 of 62 (53%) patients receiving placebo and 12 of 60 (20%) patients receiving abatacept (p=0.0003). During the double-blind period, there was no difference in the frequency of AEs between the two groups. Few SAEs were reported with no serious infections, opportunistic infections, or serious autoimmune disorders.
Abatacept was also used in a case of refractory JIA uveitis resistant to infliximab and rituximab, and the response was good. Abatacept may be a useful alternative for treating JIA children with associated uveitis and must, therefore, be considered as a viable treatment option.
Rituximab (MabThera/Rituxan), a selective B-celldepleting agent, is a chimeric anti-CD20 mAb. B lymphocytes have been implicated in the pathogenesis of rheumatoid synovitis. The precise role of B cells has not been elucidated, but potential mechanisms include an antigen-presenting function, secretion of proinflammatory cytokines and costimulation of T cells. In this context, B cell depletion with rituximab has recently emerged as a potential treatment option for patients with RA. In randomized controlled studies, rituximab has been shown to be effective in patients with RA[81,82] and approved by the FDA for treatment of adult patients with moderate to severe RA. There are few published case reports on the use of rituximab in children with refractory JIA.[83-85] On the other hand, in an oral presentation at the 3rd Europaediatrics Congress 2008, Alexeyeva et al. reported on 33 patients (16 boys and 17 girls) with severe systemic (n=24) or articular (n=9) JIA refractory to immunosuppressive therapy including oral and parenteral glucocorticoids treated with rituximab. In this study, 24 patients refractory to TNF-α blockers and rituximab had been shown to produce a marked therapeutic effect including a decrease in clinical and laboratory disease activity parameters. They suggested that rituximab might be a promising therapeutic option in severe refractory JIA. Thus, further RCTs are needed to clarify the role of rituximab in children with severe refractory JIA.
Thalidomide (thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of TNF-α in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. Preliminary studies have demonstrated that thalidomide may be beneficial for children with severe SOJIA.[87,88] Lehman et al. reported the use of thalidomide in the dose range 2 to 5 mg/kg/day administered orally in 13 children with refractory SOJIA. Ten of the 13 children had improved by 50% or more according to ACR Pedi response criteria. In an another small study, García-Carrasco et al. reported three cases of recalcitrant SOJIA that had improved dramatically after treatment with thalidomide. The most serious toxicity associated with thalidomide is its documented human teratogenicity. Based on present knowledge, thalidomide must not be used at any time during pregnancy. Somnolence, dizziness, and rash are the most commonly observed AEs associated with the use of thalidomide. Thalidomide is also associated with peripheral neuropathy and neutropenia.
Leflunomide (Arava), an orally administered inhibitor of pyrimidine synthesis, has been shown to be a safe and effective long-term therapy for adults with RA. In a multinational RCT, Silverman et al. enrolled 94 children aged 3 to 17 years to compare the safety and efficacy of oral leflunomide with oral MTX in the treatment of polyarticular JIA. At week 16, the rates of ACR Pedi 50 responses were 60% in the leflunomide group and 77% in the MTX group (p=0.10), and the rates of ACR Pedi 70 responses were 43% and 60% respectively (p=0.14). In both groups, the improvements achieved at week 16 were maintained at week 48. After 48 weeks of treatment, MTX and leflunomide both resulted in high rates of clinical improvement, and the ACR pedi 30, 50, and 70 responses were similar between the two groups (79%, 76%, and 70% for leflunomide, and 91%, 86%, and 83% for MTX). The incidence of treatment-related AEs was similar in the leflunomide group and the MTX group. The most commonly reported AEs were gastrointestinal symptoms including liver function test abnormalities, headache, nasopharyngeal symptoms, and reversible alopecia. Like thalidomide, leflunomide is also a known teratogen, so women of childbearing potential must not be started on leflunomide until pregnancy is excluded.
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
Autologous stem cell transplantation has been used in patients with severe resistant JIA. For children with severe disease who fail to achieve disease control despite the use of multiple drugs including anti-TNF and anti- IL-6 receptor treatment, both allogenic and ASCT may offer an alternative option for disease remission. However, the procedure still carries a high mortality rate for an illness that does not typically have a fatal outcome. Results from 34 children with refractory SOJIA (29 children) and polyarticular disease who have undergone ASCT at multiple centers across Europe have been published. Data demonstrated 18/34 (53%) patients had a complete response, six showed a partial response, and seven did not respond. The incidence of infectious complications was high and three children died. All deaths occured in patients with SOJIA due to MAS complicated by infection. Autologous stem cell transplantation protocols were subsequently modified in 1999 to decrease the depletion of T-cells. After these changes, there have been no ASCT-related deaths among 11 patients who have received the modified regimen. Although this procedure has helped a number of children whose disease was intractable, the authors point to the risk of high treatment-related morbidity and mortality. It is hoped that with the help of more effective anticytokine treatments such highrisk procedures will not be necessary in the future.
In conclusion, juvenile idiopathic arthritis is the most common rheumatic childhood disease that is associated with significant morbidity including functional disability and ocular damage. Prior to the era of biologicals, more than 25% of polyarticular and nearly 50% of systemic patients with JIA had functional limitations, and two-thirds had radiographically evident damage five years after onset. New and exciting alternative medications are emerging for children resistant to standard therapy. New data from large RCTs have showed the efficacy of TNF-α inhibitors, the T-cell costimulation modifier abatacept, and leflunomide for the treatment of polyarticular JIA. Anti-IL-1 and anti-IL-6 biologicals, particularly for SOJIA patients, look very promising as well. The mAbs to TNF-α appear to be more effective in treating chronic uveitis associated with JIA than etanercept; however, treatment still needs to be developed. The hope is that recent changes in treatment approaches will result in marked improvement in long-term functional outcomes of patients with JIA.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The authors received no financial support for the research and/or authorship of this article.